↑ 疾患リストへ ← 戻る

 4. 原発性側索硬化症 [臨床試験数:6,薬物数:12(DrugBank:7),標的遺伝子数:17,標的パスウェイ数:29] 

Searched query = "Primary lateral sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03929068May 13, 201915 July 2019Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral SclerosisSinemet in ALS and PLSAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: carbidopa-levodopa;Drug: Placebo Oral TabletWashington University School of MedicineRecruiting18 YearsN/AAll15Phase 1United States
2EUCTR2018-000142-18-FI09/05/201821 May 2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative careAmyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Dexdor
Pharmaceutical Form: Concentrate for concentrate for solution for infusion
INN or Proposed INN: DEXMEDETOMIDINE
CAS Number: 113775-47-6
Trade Name: Ketanest-S
Pharmaceutical Form: Infusion
INN or Proposed INN: ESKETAMINE
CAS Number: 33643-46-8
Turku University HospitalAuthorisedFemale: yes
Male: yes
20Phase 4Finland
3NCT03067857September 201618 June 2018Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseAutologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy;Progressive Bulbar PalsiesBiological: Stem CellsStem Cells ArabiaNot recruiting24 Years70 YearsAll40Phase 1/Phase 2
4NCT02868567March 20169 September 2019Use of Dalfampridin in Primary Lateral SclerosisA Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral SclerosisMotor Neuron Disease, UpperDrug: dalfampridineWeill Medical College of Cornell UniversityHospital for Special Surgery, New YorkRecruiting18 Years99 YearsAll35Phase 1United States
5EUCTR2011-004798-99-DE27/02/201327 October 2014Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS)Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) - Pyrimethamine In Familial ALSFamilial amyotrophic lateral sclerosis (FALS)
MedDRA version: 14.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Daraprim
Pharmaceutical Form: Tablet
INN or Proposed INN: PYRIMETHAMINE
CAS Number: 58-14-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Weill Medical College of Cornell UniversityNot RecruitingFemale: yes
Male: yes
40United States;Germany;Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00324454May 200619 February 2015Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseA Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular AtrophyBiological: LevetiracetamDuke UniversityUCB PharmaNot recruiting18 YearsN/ABoth20Phase 2United States

先頭へ